Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants
- DOI
- 10.1080/21645515.2025.2516948
- Published
- 2025-07-17
- Container
- Human Vaccines & Immunotherapeutics
- Publisher
- Informa UK Limited
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1080/21645515.2025.2516948,
title = {Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants},
author = {Yulei He and Fengli Zhao and Xiao Yang and Shasha Xing and Feifeng Xi and Fen Shen and Lin Yang and Guijun Ning and Fang Sun and Rui Wang and Qiong Shou and Rong Fu and Chang Chen and Anushua Sinha and Xueyan Liao},
year = {2025},
journal = {Human Vaccines \& Immunotherapeutics},
doi = {10.1080/21645515.2025.2516948},
url = {https://doi.org/10.1080/21645515.2025.2516948}
}RIS
TY - JOUR TI - Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants AU - Yulei He AU - Fengli Zhao AU - Xiao Yang AU - Shasha Xing AU - Feifeng Xi AU - Fen Shen AU - Lin Yang AU - Guijun Ning AU - Fang Sun AU - Rui Wang AU - Qiong Shou AU - Rong Fu AU - Chang Chen AU - Anushua Sinha AU - Xueyan Liao PY - 2025 JO - Human Vaccines & Immunotherapeutics DO - 10.1080/21645515.2025.2516948 UR - https://doi.org/10.1080/21645515.2025.2516948 ER -
APA
He, Y., Zhao, F., Yang, X., Xing, S., Xi, F., Shen, F., Yang, L., Ning, G., Sun, F., Wang, R., Shou, Q., Fu, R., Chen, C., Sinha, A., & Liao, X. (2025). Phase I open-label study of the respiratory syncytial virus monoclonal antibody clesrovimab: Safety and tolerability in healthy Chinese participants. Human Vaccines & Immunotherapeutics. https://doi.org/10.1080/21645515.2025.2516948
Source records
- crossref · retrieved 2026-09-27T14:17:50.775Z